Hogan Lovells advises Recordati on the agreements for the acquisition of the manufacturing and commercialization rights to Inrebic® in Japan

Recordati has received advice from Hogan Lovells regarding the agreements for the purchase of the manufacture and commercialization rights to Inrebic® in Japan from Impact Biomedicines, a business that is fully owned by Bristol-Myers Squibb K.K. Myelofibrosis is treated with the medication Inrebic® (generic name: fedratinib hydrochloride hydrate).